Spots Global Cancer Trial Database for emd 525797
Every month we try and update this database with for emd 525797 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | NCT01360840 | Prostate Cancer... | EMD 525797 EMD 525797 Placebo Standard of Car... | 18 Years - | EMD Serono | |
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer | NCT01008475 | Metastatic Colo... | EMD 525797 250 ... EMD 525797 500 ... EMD 525797 750 ... EMD 525797 1000... Cetuximab Irinotecan | 18 Years - | Merck KGaA, Darmstadt, Germany | |
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | NCT01360840 | Prostate Cancer... | EMD 525797 EMD 525797 Placebo Standard of Car... | 18 Years - | EMD Serono | |
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer | NCT00958477 | Prostate Cancer Bone Metastases | EMD 525797 | 18 Years - | Merck KGaA, Darmstadt, Germany | |
EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases | NCT00848510 | Colorectal and ... | EMD 525797 | 18 Years - | Merck KGaA, Darmstadt, Germany | |
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | NCT01360840 | Prostate Cancer... | EMD 525797 EMD 525797 Placebo Standard of Car... | 18 Years - | EMD Serono |